# Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

> **NCT06538623** · PHASE2 · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Neoplasm Metastasis
- Hepatic Metastasis of Pancreatic Cancer

## Interventions

- **DRUG:** Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin
- **DRUG:** Tegodor

## Key facts

- **NCT ID:** NCT06538623
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-23
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538623, "Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06538623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*